Wegovy vs Mounjaro for Men: Which Works Better?

Quick Comparison

When comparing Wegovy vs Mounjaro for men, it is important to understand that while both are revolutionary injectable medications for weight management, they belong to slightly different classes of drugs. Wegovy (semaglutide) is a pure GLP-1 receptor agonist, while Mounjaro (tirzepatide) is a "twincretin," targeting both GLP-1 and GIP receptors. This dual-action approach often leads to different results in terms of total weight loss and side effect profiles.

For men looking to optimize their body composition, the choice often comes down to how much weight needs to be lost and how the body responds to the specific hormonal signals these drugs send. Below is a high-level comparison of the two medications based on clinical trial data and FDA-approved labeling.

Feature	Wegovy (Semaglutide)	Mounjaro / Zepbound (Tirzepatide)
Mechanism	GLP-1 Receptor Agonist	Dual GLP-1 & GIP Receptor Agonist
Avg. Weight Loss	~15% of body weight	~21% to 22.5% of body weight
Dosing Frequency	Once weekly injection	Once weekly injection
Max Dose	2.4 mg	15 mg
FDA Approval	Obesity & Cardiovascular Risk Reduction	Type 2 Diabetes (Mounjaro) / Obesity (Zepbound)
Common Side Effects	Nausea, vomiting, constipation	Nausea, diarrhea, decreased appetite
Estimated Cost	$1,300+ (Brand) / Lower for Compounded	$1,000+ (Brand) / Lower for Compounded

How They Work Differently

To understand the Wegovy vs Mounjaro men debate, we have to look at the hormones they mimic. Wegovy is a selective glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a hormone naturally produced in your gut that tells your brain you are full, slows down gastric emptying (how fast food leaves your stomach), and prompts the pancreas to release insulin. For men, this means "food noise"—that constant internal chatter about the next meal—is significantly silenced.

Mounjaro (and its weight-loss-branded twin, Zepbound) takes this a step further. It is a dual agonist, meaning it mimics GLP-1 but also mimics Glucose-dependent Insulinotropic Polypeptide (GIP). Think of GIP as a partner hormone that enhances the effects of GLP-1. While GLP-1 focuses heavily on satiety and slowing the gut, GIP appears to play a larger role in how the body breaks down fat and manages energy storage in adipose tissue. Some researchers believe GIP also helps mitigate some of the nausea associated with GLP-1 stimulation.

Clinically, this dual-receptor activity is why tirzepatide (Mounjaro) often outperforms semaglutide (Wegovy) in head-to-head comparisons. By attacking metabolic dysfunction from two angles, Mounjaro can often achieve deeper levels of insulin sensitivity. For men struggling with "stubborn" visceral fat—the dangerous fat stored around internal organs—this dual action can be particularly effective at shifting the metabolic needle.

Weight Loss: Head to Head

When we look at the data, the "winner" in terms of raw numbers is usually tirzepatide. The clinical trial programs for these drugs—STEP for Wegovy and SURMOUNT for Mounjaro/Zepbound—provide the clearest picture. In the STEP 1 trial, participants taking 2.4 mg of semaglutide lost an average of 14.9% of their body weight over 68 weeks. For a 250-pound man, that is a loss of roughly 37 pounds.

In contrast, the SURMOUNT-1 trial for tirzepatide showed even more dramatic results. Participants on the highest dose (15 mg) lost an average of 20.9% to 22.5% of their body weight over 72 weeks. Using that same 250-pound man as an example, the loss would be closer to 52–56 pounds. A more recent head-to-head real-world study published in JAMA Internal Medicine confirmed these findings, noting that patients on tirzepatide were significantly more likely to achieve 10%, 15%, and 20% weight loss compared to those on semaglutide.

However, "more" isn't always "better" for every man. Rapid weight loss can sometimes lead to a higher percentage of muscle mass loss if not managed correctly. Men who are already active or who are combining GLP-1s with TRT may find that the steady, slightly more moderate pace of Wegovy allows them to preserve more lean tissue while still hitting their goals. At HeydayMD, we focus on the quality of weight loss, not just the number on the scale, ensuring that the weight you lose is fat, not muscle.

Side Effects Compared

Both medications share a similar side effect profile because they both utilize the GLP-1 pathway. The most common complaints are gastrointestinal: nausea, diarrhea, constipation, and occasional vomiting. These symptoms are usually most prominent when first starting the medication or when increasing the dose. Most men find that these issues subside after a few weeks as the body adapts to the hormone levels.

Interestingly, some clinical data and anecdotal evidence suggest that tirzepatide (Mounjaro) may have a slightly more favorable side effect profile at "equipotent" doses. Because the GIP component of Mounjaro may have a stabilizing effect on the brain's nausea centers, some men report feeling "less sick" on Mounjaro than they did on Wegovy. However, because Mounjaro is more potent, the side effects can be more intense if the dose is escalated too quickly.

Common side effects for both include:

• Nausea: Often triggered by overeating or eating high-fat foods.
• Constipation: Due to slowed gastric emptying; increasing fiber and water intake is essential.
• Fatigue: Often a result of a significant caloric deficit rather than the drug itself.
• Acid Reflux: Food staying in the stomach longer can lead to heartburn.

For men, a specific concern is "lean mass loss." Because these drugs suppress appetite so effectively, it is easy to under-eat protein. This can lead to a drop in strength and even a temporary dip in testosterone levels if the body enters a state of extreme stress. This is why many men choose to pair weight loss treatment with TRT to protect their muscle and metabolic rate.

Cost and Access

The "Wegovy vs Mounjaro men" decision often hits a roadblock at the pharmacy counter. Both medications are expensive, with list prices often exceeding $1,000 per month without insurance. Wegovy is FDA-approved specifically for chronic weight management, which makes it easier to get covered by some insurance plans—provided you meet specific BMI criteria. Mounjaro is technically approved for Type 2 Diabetes, though its sister drug Zepbound is approved for weight loss.

Insurance coverage is notoriously fickle. Many plans exclude weight loss medications entirely. For men whose insurance says "no," there are several alternatives:

1. Manufacturer Savings Cards: Both Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro/Zepbound) offer coupons that can bring the price down significantly for those with commercial insurance.
2. Compounded Medications: Many telehealth clinics, including HeydayMD, offer access to compounded semaglutide or tirzepatide. These are prepared by specialized pharmacies and are often a fraction of the cost of the brand-name pens, making treatment accessible for men paying out-of-pocket.
3. HSA/FSA Funds: Since these are prescription medications for a diagnosed medical condition (obesity or overweight with comorbidities), they are generally eligible for health savings account spending.

Which Is Better for Men?

The "better" drug depends on your specific health profile and goals. If you are a man with a significant amount of weight to lose (50+ pounds) and you have struggled with insulin resistance or "prediabetes," Mounjaro (tirzepatide) is likely the more powerful tool. Its dual-action mechanism is specifically designed to correct the metabolic "brokenness" that makes losing weight so difficult for some men.

On the other hand, Wegovy (semaglutide) might be the better choice if you have a history of cardiovascular issues. Wegovy has been specifically FDA-approved to reduce the risk of major adverse cardiovascular events (like heart attacks and strokes) in adults with heart disease and obesity. For men in their 50s and 60s where heart health is the primary concern, Wegovy offers a layer of protection that is backed by years of robust data.

Another factor for men is the impact on testosterone. Obesity is one of the leading causes of low T, as adipose tissue (fat) converts testosterone into estrogen. Both drugs will help raise natural testosterone levels by reducing fat mass. However, if you are already dealing with symptoms of low testosterone, you should consider how these medications fit into a broader hormone optimization plan. Losing weight is great, but losing weight while maintaining high T levels is how you achieve the "alpha" body composition—low fat, high muscle.

How to Decide

Choosing between Wegovy and Mounjaro doesn't have to be a coin flip. At HeydayMD, we recommend a framework based on four key factors:

• Your Starting Point: If your BMI is over 35 and you have metabolic syndrome, the extra horsepower of Mounjaro may be worth it. If you have less to lose, Wegovy is a tried-and-true option.
• Your Budget: Check your insurance formulary first. If neither is covered, compare the costs of compounded semaglutide vs. compounded tirzepatide. Semaglutide is generally the more affordable entry point.
• Your Tolerance: If you are sensitive to medications, starting with a low dose of semaglutide is a common path. If you've tried semaglutide and plateaued, switching to tirzepatide is a frequent and successful strategy.
• Your Hormonal Health: Don't ignore your testosterone. Weight loss is more effective and sustainable when your hormones are balanced.

The best way to decide is to speak with a provider who understands the nuances of men's health. We don't just look at the scale; we look at your bloodwork, your lifestyle, and your long-term goals. Whether it's semaglutide, tirzepatide, or a combination of weight loss therapy and TRT, the goal is to get you back to feeling like your best self. Ready to take the next step? HeydayMD can help you evaluate your options and start your journey toward a leaner, healthier life.